{
 "set": "Round 2 blind benchmark answer keys",
 "built": "2026-11-10",
 "rubric": "../RUBRIC.md (4 marks: figure, cites, source contains figure, as-of)",
 "keys": [
  {
   "id": "R2-01",
   "ticker": "VATE",
   "category": "dilution",
   "answer": "Up to $31,000,000 of common stock; sales agent Jefferies LLC (Open Market Sale Agreement dated August 10, 2026).",
   "accepted_variants": [
    "$31 million",
    "31,000,000",
    "Jefferies"
   ],
   "as_of": "August 10, 2026 (date of Sales Agreement and prospectus supplement)",
   "primary_source": [
    {
     "accession": "0001006837-26-000078",
     "form": "424B5",
     "filing_date": "2026-08-10",
     "url": "https://www.sec.gov/Archives/edgar/data/1006837/000100683726000078/vate-2026atmxprosupp.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1006837/000100683726000078/"
    }
   ],
   "supporting_passage": "mxprosupp.htm 424B5 Document Filed Pursuant to Rule 424(b)(5) Registration No. 333-274760 PROSPECTUS SUPPLEMENT (To Prospectus dated October 6, 2023) Up to $31,000,000 Common Stock We have entered into an Open Market Sale Agreement SM , dated August 10, 2026 (the “Sales Agreement”), with Jefferies LLC (“Jefferies”), relating to the sale of shares of our common stoc ... r 6, 2023) Up to $31,000,000 Common Stock We have entered into an Open Market Sale Agreement SM , dated August 10, 2026 (the “Sales Agreement”), with Jefferies LLC (“Jefferies”), relating to the sale of shares of our common stock offered by this prospectus supplement. In accordance with the terms of the Sales Agreement, under this prospectus supplement we may o",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-02",
   "ticker": "VEEA",
   "category": "dilution",
   "answer": "Up to $4,353,000 of common stock; sales agent Roth Capital Partners, LLC (sales agreement dated August 13, 2026).",
   "accepted_variants": [
    "$4.353 million",
    "4,353,000",
    "Roth Capital Partners",
    "Roth"
   ],
   "as_of": "August 13, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-088706",
     "form": "424B5",
     "filing_date": "2026-08-13",
     "url": "https://www.sec.gov/Archives/edgar/data/1840317/000121390026088706/ea0301578-424b5_veea.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1840317/000121390026088706/"
    }
   ],
   "supporting_passage": "htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration Statement 333-297083 PROSPECTUS SUPPLEMENT (To Prospectus dated July 1, 2026) Up to $4,353,000 Common Stock We have entered into a sales agreement dated as of August 13, 2026, or the Sales Agreement, with Roth Capital Partners, LLC, or the Agent, relating to the sale of shares of our common st ... us dated July 1, 2026) Up to $4,353,000 Common Stock We have entered into a sales agreement dated as of August 13, 2026, or the Sales Agreement, with Roth Capital Partners, LLC, or the Agent, relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement. In accordance with the terms of such Sales Agreement and this pr",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-03",
   "ticker": "AZTR",
   "category": "dilution",
   "answer": "Up to $3,503,232 of common stock; sales agent A.G.P./Alliance Global Partners (Sales Agreement dated September 28, 2026).",
   "accepted_variants": [
    "$3.5 million (3,503,232 exact)",
    "A.G.P.",
    "Alliance Global Partners"
   ],
   "as_of": "September 28, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-044593",
     "form": "424B5",
     "filing_date": "2026-09-28",
     "url": "https://www.sec.gov/Archives/edgar/data/1701478/000149315226044593/form424b5.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1701478/000149315226044593/"
    }
   ],
   "supporting_passage": "24B5 1 form424b5.htm 424B5 F iled Pursuant to Rule 424(b)(5) Registration No. 333-280648 Prospectus Supplement (To the Prospectus dated July 8, 2024) Up to $3,503,232 of Shares of Common Stock Azitra, Inc., a Delaware corporation (“Azitra,” the “Company,” “we,” “us” or “our”), has entered into a Sales Agreement, dated September 28, 2026 (the “Sales Agreement”) wit ... corporation (“Azitra,” the “Company,” “we,” “us” or “our”), has entered into a Sales Agreement, dated September 28, 2026 (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), relating to the offer and sale of shares of our common stock, par value $0.0001 per share, from time to time, offered by this prospectus supplement and the accompanying base prospectus. I",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-04",
   "ticker": "QNRX",
   "category": "dilution",
   "answer": "Up to $11,000,000 of ADSs (each ADS represents 35 ordinary shares); sales agent Leerink Partners LLC (Sales Agreement dated November 4, 2026).",
   "accepted_variants": [
    "$11 million",
    "11,000,000",
    "Leerink Partners",
    "Leerink"
   ],
   "as_of": "November 4, 2026",
   "primary_source": [
    {
     "accession": "0001104659-26-122776",
     "form": "424B5",
     "filing_date": "2026-11-04",
     "url": "https://www.sec.gov/Archives/edgar/data/1671502/000110465926122776/tm2628246d2_424b5.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1671502/000110465926122776/"
    }
   ],
   "supporting_passage": "tm2628246d2_424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-299668 PROSPECTUS SUPPLEMENT (To Prospectus dated November 4, 2026) Up to $11,000,000 American Depositary Shares Representing Ordinary Shares We have entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), dated November 4, 2026, relating ... , 2026) Up to $11,000,000 American Depositary Shares Representing Ordinary Shares We have entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), dated November 4, 2026, relating to the sale of American Depositary Shares (“ADSs”), each representing 35 of our ordinary shares, no par value (“Ordinary Shares”), offered by th",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-05",
   "ticker": "NTRP",
   "category": "dilution",
   "answer": "Up to $6,500,000 of common stock; agent Titan Partners Securities LLC.",
   "accepted_variants": [
    "$6.5 million",
    "6,500,000",
    "Titan Partners"
   ],
   "as_of": "August 31, 2026 (filing date; prospectus supplement to prospectus dated November 21, 2025)",
   "primary_source": [
    {
     "accession": "0001493152-26-040864",
     "form": "424B5",
     "filing_date": "2026-08-31",
     "url": "https://www.sec.gov/Archives/edgar/data/788611/000149315226040864/form424b5.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/788611/000149315226040864/"
    }
   ],
   "supporting_passage": "form424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) File No. 333-291260 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 21, 2025) NextTrip, Inc. Up to $6,500,000 Common Stock We have entered into a sales agreement with Titan Partners Securities LLC (the “Agent”) relating to the issuance and sale of our common stock offered by this prospectus. In accordance wi ... ROSPECTUS SUPPLEMENT (To Prospectus Dated November 21, 2025) NextTrip, Inc. Up to $6,500,000 Common Stock We have entered into a sales agreement with Titan Partners Securities LLC (the “Agent”) relating to the issuance and sale of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our comment stock ",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-06",
   "ticker": "NNVC",
   "category": "dilution",
   "answer": "Up to $2,374,774 of common stock; sales agent D. Boral Capital LLC. (Amendment No. 2 dated October 21, 2026 updates the maximum amount under the July 17, 2026 prospectus supplement; the figure reflects Form S-3 baby-shelf limits.)",
   "accepted_variants": [
    "$2.37 million",
    "2,374,774",
    "D. Boral",
    "D. Boral Capital"
   ],
   "as_of": "October 21, 2026",
   "primary_source": [
    {
     "accession": "0001104659-26-117595",
     "form": "424B5",
     "filing_date": "2026-10-21",
     "url": "https://www.sec.gov/Archives/edgar/data/1379006/000110465926117595/tm2627711d1_424b5.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1379006/000110465926117595/"
    }
   ],
   "supporting_passage": "s Supplement dated July 17, 2026 (To Prospectus Dated June 15, 2026) Filed pursuant to Rule 424(b)(5) Registration No. 333-296550 NANOVIRICIDES, INC. Up to $2,374,774 Common Stock This Amendment No. 2 to Prospectus Supplement (this “Amendment”) amends and supplements the information in our prospectus, dated June 15, 2026 (the “Prospectus”), and the prospectus supp ...  to update the maximum amount of shares of our common stock, par value $0.00001 per share, that we may issue and sell from time to time through or to D. Boral Capital LLC (the “Agent”) as sales agent or principal, pursuant to the terms of our previously announced At Market Issuance Sales Agreement, dated July 17, 2026, between us and the Agent (the “Sales Agreement”).",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: the earlier July 17 supplement and its July 27 amendment carried different maximums; the Amendment No. 2 figure is the operative one."
  },
  {
   "id": "R2-07",
   "ticker": "WKSP",
   "category": "dilution",
   "answer": "Up to $493,000 of common stock; sales agent H.C. Wainwright & Co., LLC (At the Market Offering Agreement dated September 30, 2022, as amended November 14, 2025).",
   "accepted_variants": [
    "$493,000",
    "H.C. Wainwright",
    "Wainwright"
   ],
   "as_of": "August 7, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-036615",
     "form": "424B5",
     "filing_date": "2026-08-07",
     "url": "https://www.sec.gov/Archives/edgar/data/1096275/000149315226036615/form425b5.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1096275/000149315226036615/"
    }
   ],
   "supporting_passage": "uant to Rule 424(b)(5) Registration No. 333-291582 PROSPECTUS SUPPLEMENT (To Prospectus dated December 12, 2025) WORKSPORT LTD Shares of Common Stock Up to $493,000 This prospectus supplement (the “Prospectus Supplement”) amends and supplements the prospectus supplement dated December 12, 2025 (the “ATM Prospectus Supplement”) and the prospectus dated December 1 ... rsuant to that certain At the Market Offering Agreement dated as of September 30, 2022, as amended on November 14, 2025 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”). Our common stock is listed on The Nasdaq Capital Market under the symbol “WKSP.” On August 6, 2026, the last reported sale price of our common stock on The Nasdaq Capital Market was $",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: the underlying ATM program was originally far larger; the August supplement limits current capacity to $493,000 under baby-shelf rules."
  },
  {
   "id": "R2-08",
   "ticker": "OGEN",
   "category": "dilution",
   "answer": "677,687 warrants (including 660,000 Series H Warrants exercisable into Series H Convertible Preferred Stock; the other 17,687 are common-stock warrants).",
   "accepted_variants": [
    "677,687"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-037749",
     "form": "10-Q",
     "filing_date": "2026-08-13",
     "url": "https://www.sec.gov/Archives/edgar/data/1174940/000149315226037749/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1174940/000149315226037749/"
    }
   ],
   "supporting_passage": "nding Exercise Price Expiration Date 2,341 (1) $ 56.25 2/27/2029 1,834 (1) $ 37.50 6/29/2029 13,512 (1) $ 20.70 9/4/2029 660,000 (2) $ 25.00 7/2/2030 677,687 (1) Represents warrants to purchase common stock, with each such warrant exercisable into one share of common stock. (2) Comprised of 660,000 Series H Warrants, which, upon exercise, will result in t ... /2/2030 677,687 (1) Represents warrants to purchase common stock, with each such warrant exercisable into one share of common stock. (2) Comprised of 660,000 Series H Warrants, which, upon exercise, will result in the issuance of 660,000 shares of Series H Convertible Preferred Stock, which, at the current Conversion Price of $ 1.00 per share and based on the Stated Value ",
   "xbrl_facts": [
    {
     "tag": "ClassOfWarrantOrRightOutstanding",
     "value": 677687,
     "period_end": "2026-06-30"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: 660,000 of the total are Series H warrants that convert to preferred, not common."
  },
  {
   "id": "R2-09",
   "ticker": "AIFF",
   "category": "dilution",
   "answer": "14,567,404 warrants outstanding at June 30, 2026, weighted average exercise price $2.84 (includes 13,666,666 PIPE 2026 warrants at $2.19; 900,738 outstanding at Dec 31, 2025).",
   "accepted_variants": [
    "14,567,404",
    "$2.84"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001437749-26-026822",
     "form": "10-Q",
     "filing_date": "2026-08-11",
     "url": "https://www.sec.gov/Archives/edgar/data/803578/000143774926026822/aiff20260630_10q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/803578/000143774926026822/"
    }
   ],
   "supporting_passage": "Life (Years) Outstanding warrants, December 31, 2025 900,738 $ 16.26 6.65 PIPE 2026 warrants 13,666,666 2.19 - Exercised - - - Warrants Expired - - - Outstanding warrants, June 30, 2026 14,567,404 $ 2.84 4.58 12 Table of Contents c. Warrants exercisable for little or no consideration Warrants exercisable for little or no consideration are fully vested warrants that allow the holders to acquire a spec",
   "xbrl_facts": [
    {
     "tag": "ClassOfWarrantOrRightOutstanding",
     "value": 14567404,
     "period_end": "2026-06-30"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: December 31, 2025 balance was only 900,738."
  },
  {
   "id": "R2-10",
   "ticker": "DRMA",
   "category": "dilution",
   "answer": "5,424,598 shares of common stock (no pre-funded warrants outstanding at June 30, 2026).",
   "accepted_variants": [
    "5,424,598"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-037127",
     "form": "10-Q",
     "filing_date": "2026-08-11",
     "url": "https://www.sec.gov/Archives/edgar/data/1853816/000149315226037127/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1853816/000149315226037127/"
    }
   ],
   "supporting_passage": "s of December 31, 2025, which were exercised during the first quarter of 2026, leaving no pre-funded warrants outstanding as of June 30, 2026. 16 The warrants outstanding as of June 30, 2026, are exercisable into 5,424,598 shares of Common Stock which had a fair value of $ 1.29 per share based on the closing trading price on June 30, 2026. The aggregate intrinsic value of warrants outstanding as of June 30, 2026, is calculate",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "XBRL prior-year (Dec 31, 2025) warrant count was 5,424,617; the June 30, 2026 figure is 5,424,598."
  },
  {
   "id": "R2-11",
   "ticker": "GANX",
   "category": "dilution",
   "answer": "5,267,652 warrants outstanding at June 30, 2026, weighted average exercise price $2.37 (down from 5,759,453 at December 31, 2025).",
   "accepted_variants": [
    "5,267,652",
    "$2.37"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001104659-26-094048",
     "form": "10-Q",
     "filing_date": "2026-08-11",
     "url": "https://www.sec.gov/Archives/edgar/data/1819411/000110465926094048/ganx-20260630x10q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1819411/000110465926094048/"
    }
   ],
   "supporting_passage": "ing Exercisable Exercise Price November 24, 2028 3,361,484 3,361,484 $ 2.75 June 17, 2029 106,914 106,914 1.69 July 17, 2030 1,799,254 1,799,254 1.71 Outstanding as of June 30, 2026 5,267,652 5,267,652 $ 2.37 The following table summarizes the Company’s warrants activity for the six months ended June 30, 2026: Weighted Average Warrants Exercise Price Outstanding as of December 31, 2025 5,759,453 $ 2.31 Ex",
   "xbrl_facts": [
    {
     "tag": "ClassOfWarrantOrRightOutstanding",
     "value": 5267652,
     "period_end": "2026-06-30"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-12",
   "ticker": "PULM",
   "category": "dilution",
   "answer": "317,585 shares (36,538 at $14.99 expiring Dec 15, 2026 plus 281,047 at $13.99 expiring Dec 17, 2026).",
   "accepted_variants": [
    "317,585"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-037594",
     "form": "10-Q",
     "filing_date": "2026-08-13",
     "url": "https://www.sec.gov/Archives/edgar/data/1574235/000149315226037594/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1574235/000149315226037594/"
    }
   ],
   "supporting_passage": "tion Date Number of Shares Underlying Warrants December 17, 2021 $ 14.99 December 15, 2026 36,538 December 17, 2021 $ 13.99 December 17, 2026 281,047 Total 317,585 8. Stock-based Compensation The Company sponsored the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan (the “Incentive Plan”), which expired on June 1 ... were no warrants issued or exercised during the six months ended June 30, 2026. During the six months ended June 30, 2026, warrants to purchase up to 65,003 shares of common stock at a weighted-average exercise price of $ 49.99 per share expired. The following represents a summary of the warrants outstanding and exercisable at June 30, 2026, all of which are equity-classified:",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: 65,003 warrants expired during the six months; that is not the outstanding count."
  },
  {
   "id": "R2-13",
   "ticker": "WHLR",
   "category": "reverse_split",
   "answer": "One-for-nine (1-for-9) reverse split, effective at 5:00 p.m. Eastern Time on September 21, 2026.",
   "accepted_variants": [
    "1-for-9",
    "one-for-nine",
    "1:9",
    "September 21, 2026"
   ],
   "as_of": "Effective September 21, 2026, 5:00 p.m. ET (8-K filed September 17, 2026)",
   "primary_source": [
    {
     "accession": "0001527541-26-000349",
     "form": "8-K",
     "filing_date": "2026-09-17",
     "url": "https://www.sec.gov/Archives/edgar/data/1527541/000152754126000349/whlr-20260917.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1527541/000152754126000349/"
    }
   ],
   "supporting_passage": " 8-K is incorporated herein by reference. Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Charter Amendments for One-for-nine Reverse Stock Split On September 17, 2026, in connection with a one-for-nine reverse stock split (the “ Reverse Stock Split ”) of the common stock, $0.01 par value per share (the \"Common Stock\"), of Wheeler Real Estate  ... ate Department of Assessments and Taxation of Maryland that provide for: i a one-for-nine Reverse Stock Split of the Common Stock, to be effective at 5:00 p.m. Eastern Time (the “ Effective Time ”) on September 21, 2026 (the “ First Amendment ”); and ii the par value of the Common Stock to be decreased from $0.09 per share (as a result of the one-for-nine Reverse Stock ",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: Wheeler also did 1-for-4 (effective Aug 26) and 1-for-6 (effective Oct 29) splits in the same quarter, and the effective date is four days after the 8-K filing date."
  },
  {
   "id": "R2-14",
   "ticker": "CDT",
   "category": "reverse_split",
   "answer": "8-K filed Sept 25, 2026: one-for-twenty-five (1-for-25), effective September 28, 2026 at 5:00 p.m. ET. 8-K filed Nov 4, 2026: one-for-twenty (1-for-20), effective November 5, 2026 at 5:00 p.m. ET.",
   "accepted_variants": [
    "1-for-25 on September 28, 2026",
    "1-for-20 on November 5, 2026"
   ],
   "as_of": "September 28, 2026 and November 5, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-044248",
     "form": "8-K",
     "filing_date": "2026-09-25",
     "url": "https://www.sec.gov/Archives/edgar/data/1896212/000149315226044248/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1896212/000149315226044248/"
    },
    {
     "accession": "0001493152-26-049889",
     "form": "8-K",
     "filing_date": "2026-11-04",
     "url": "https://www.sec.gov/Archives/edgar/data/1896212/000149315226049889/form8-k.htm"
    }
   ],
   "supporting_passage": "separately as a class shall be required therefor. Effective September 28, 2026 at 5:00pm Eastern Time (the “ Reverse Stock Split Effective Time ”), a one-for-twenty-five reverse stock split of the Corporation’s Common Stock shall become effective, pursuant to which each 25 shares of Common Stock issued and outstanding and held of record by each stockholder of the Cor ... uthority to determine the exact split ratios and when to proceed with any such reverse stock splits. The Reverse Stock Split will become effective on September 28, 2026, at 5:00 p.m., Eastern Time (the “Effective Time”) and the Common Stock is expected to begin trading on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis on September 29, 2026, at mar ||| (second filing 0001493152-26-049889) g separately as a class shall be required therefor. Effective November 5, 2026 at 5:00pm Eastern Time (the “ Reverse Stock Split Effective Time ”), a one-for-twenty reverse stock split of the Corporation’s Common Stock shall become effective, pursuant to which each 20 shares of Common Stock issued and outstanding and held of record by each stockholder of the Corporation ||| (second filing 0001493152-26-049889) hen to proceed with any such reverse stock splits, to maintain compliance with Nasdaq Listing Rules. The Reverse Stock Split will become effective on November 5, 2026, at 5:00 p.m., Eastern Time (the “Effective Time”) and the Common Stock is expected to begin trading on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis on November 6, 2026, at marke",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: two splits in about five weeks; a July 16, 2026 8-K reported an earlier split that is outside the question."
  },
  {
   "id": "R2-15",
   "ticker": "VJET",
   "category": "reverse_split",
   "answer": "1-for-10 reverse split (every ten shares combined into one), expected effective at 12:01 a.m. Eastern Time on October 5, 2026.",
   "accepted_variants": [
    "1-for-10",
    "one-for-ten",
    "October 5, 2026"
   ],
   "as_of": "Effective October 5, 2026, 12:01 a.m. ET (8-K filed September 25, 2026)",
   "primary_source": [
    {
     "accession": "0001437749-26-031252",
     "form": "8-K",
     "filing_date": "2026-09-25",
     "url": "https://www.sec.gov/Archives/edgar/data/1716621/000143774926031252/vtak20260925_8k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1716621/000143774926031252/"
    }
   ],
   "supporting_passage": "se Stock Split, which are expected to become effective at 12:01 a.m., Eastern Time, on October 5, 2026 (the “Effective Time”). At the Effective Time, every ten (10) shares of Common Stock issued and outstanding or held in treasury will automatically be combined into one (1) share of Common Stock. No fractional shares will be issued. Stockholders who would otherwise be  ... with the Secretary of State of the State of Delaware to effect the Name Change and the Reverse Stock Split, which are expected to become effective at 12:01 a.m., Eastern Time, on October 5, 2026 (the “Effective Time”). At the Effective Time, every ten (10) shares of Common Stock issued and outstanding or held in treasury will automatically be combined into one (1) share of Common Stock. No f",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-16",
   "ticker": "GOSS",
   "category": "reverse_split",
   "answer": "1-for-80 reverse split; the charter amendment became effective at 11:59 p.m. Eastern Time on September 10, 2026 (split-adjusted trading began September 11, 2026).",
   "accepted_variants": [
    "1-for-80",
    "one-for-eighty",
    "September 10, 2026"
   ],
   "as_of": "Effective September 10, 2026, 11:59 p.m. ET",
   "primary_source": [
    {
     "accession": "0001728117-26-000094",
     "form": "8-K",
     "filing_date": "2026-09-11",
     "url": "https://www.sec.gov/Archives/edgar/data/1728117/000172811726000094/goss-20260910.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1728117/000172811726000094/"
    }
   ],
   "supporting_passage": " As previously disclosed, on September 9, 2026, Gossamer Bio, Inc. (the “Company”) announced that its board of directors (the “Board”) had selected a 1-for-80 ratio for the previously approved reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). On September 10, 2026, the Company filed with the Secretary of S ... ing decrease in the total number of authorized shares of capital stock) (the “Authorized Share Reduction”). The Charter Amendment became effective at 11:59 p.m. Eastern Time on September 10, 2026 (the “Effective Time”). The foregoing description of the Charter Amendment is not complete and is subject to, and qualified in its entirety by, the complete text of the Charter Amendment, which is fi",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: ratio was selected by the board from a stockholder-approved range; effective date (Sept 10, 11:59 pm) differs from first split-adjusted trading day (Sept 11)."
  },
  {
   "id": "R2-17",
   "ticker": "MYSZ",
   "category": "reverse_split",
   "answer": "1-for-8 (every eight shares combined into one), effective 4:30 p.m. Eastern Time on August 12, 2026; split-adjusted trading began August 13, 2026.",
   "accepted_variants": [
    "1-for-8",
    "one-for-eight",
    "August 12, 2026"
   ],
   "as_of": "Effective August 12, 2026, 4:30 p.m. ET",
   "primary_source": [
    {
     "accession": "0001493152-26-037389",
     "form": "8-K",
     "filing_date": "2026-08-12",
     "url": "https://www.sec.gov/Archives/edgar/data/1211805/000149315226037389/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1211805/000149315226037389/"
    }
   ],
   "supporting_passage": " 1-for-2 to 1-for-30, with the exact ratio to be determined by the Company’s board of directors (the “Board”) in its discretion. The Board approved a 1-for-8 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share, (the “Reverse Stock Split”), and on August 12, 2026, the Company filed with the Secreta ... ts Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split, which became effective as of 4:30 p.m. Eastern Time on August 12, 2026. The Company’s common stock will begin trading on a split-adjusted basis when the market opens on August 13, 2026 on the Nasdaq Capital Market. When the Reverse Stock Split became effective, every ei",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: stockholders approved a range of 1-for-2 to 1-for-30; the board set 1-for-8."
  },
  {
   "id": "R2-18",
   "ticker": "ALCE",
   "category": "reverse_split",
   "answer": "1-for-2,500 reverse stock split, effective at 12:01 a.m. Eastern Time on August 20, 2026 (certificate of amendment filed with the Delaware Secretary of State August 13, 2026).",
   "accepted_variants": [
    "1-for-2,500",
    "1-for-2500",
    "August 20, 2026"
   ],
   "as_of": "Effective August 20, 2026, 12:01 a.m. ET",
   "primary_source": [
    {
     "accession": "0001437749-26-028619",
     "form": "8-K",
     "filing_date": "2026-08-20",
     "url": "https://www.sec.gov/Archives/edgar/data/1883984/000143774926028619/alce20260820_8k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1883984/000143774926028619/"
    }
   ],
   "supporting_passage": "cles of Incorporation or Bylaws; Change in Fiscal Year. On August 20, 2026, at 12:01 a.m. Eastern Time (the “Effective Time”), the Company effected a 1-for-2,500 reverse stock split (the “Reverse Stock Split”) of all issued and outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), pursuant to a Certificate of Amen ... m 8-K is incorporated herein by reference. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On August 20, 2026, at 12:01 a.m. Eastern Time (the “Effective Time”), the Company effected a 1-for-2,500 reverse stock split (the “Reverse Stock Split”) of all issued and outstanding shares of the Company’s common stock, par value $0.0001 per sh",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: the certificate was filed Aug 13 but became effective Aug 20."
  },
  {
   "id": "R2-19",
   "ticker": "BSFC",
   "category": "reverse_split",
   "answer": "1-for-1,600 reverse split, effective under Delaware law at 12:01 a.m. Eastern Time on October 8, 2026 (certificate accepted for filing October 5, 2026).",
   "accepted_variants": [
    "1-for-1,600",
    "1-for-1600",
    "October 8, 2026"
   ],
   "as_of": "Effective October 8, 2026, 12:01 a.m. ET",
   "primary_source": [
    {
     "accession": "0001493152-26-046275",
     "form": "8-K",
     "filing_date": "2026-10-08",
     "url": "https://www.sec.gov/Archives/edgar/data/1730773/000149315226046275/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1730773/000149315226046275/"
    }
   ],
   "supporting_passage": "ny’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of one-for-one thousand six hundred (1-for-1,600) (the “Reverse Stock Split”). The Certificate of Amendment was accepted for filing by the Delaware Secretary of State on October 5, 2026 and provides that the Reverse Stock Split becomes effective un ... ed for filing by the Delaware Secretary of State on October 5, 2026 and provides that the Reverse Stock Split becomes effective under Delaware law at 12:01 a.m., Eastern Time, on October 8, 2026 (the “Effective Time”). The 1-for-1,600 ratio was selected by the Company’s Board of Directors (the “Board”) pursuant to the authority previously approved by the Company’s stockholders. FINRA advised",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: acceptance date (Oct 5) differs from effective date (Oct 8)."
  },
  {
   "id": "R2-20",
   "ticker": "CYCU",
   "category": "reverse_split",
   "answer": "One-for-eight (1-for-8) reverse split, effective August 28, 2026 (split-adjusted trading at market open that day).",
   "accepted_variants": [
    "1-for-8",
    "one-for-eight",
    "August 28, 2026"
   ],
   "as_of": "Effective August 28, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-040521",
     "form": "8-K",
     "filing_date": "2026-08-28",
     "url": "https://www.sec.gov/Archives/edgar/data/1868419/000149315226040521/form8-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1868419/000149315226040521/"
    }
   ],
   "supporting_passage": "e “Company”), a leading cybersecurity solutions provider, announced today that it will effect a reverse stock split of its common stock at a ratio of one-for-eight (the “Reverse Stock Split”). The Reverse Stock Split will become effective at August 28, 2026, and the Company’s common stock will begin trading on a split-adjusted basis on The Nasdaq Global Market  ... 0549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 28, 2026 (August 26, 2026) CYCURION, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-41214 86-3720717 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Num",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "The announcement press release (Exhibit 99.1) is dated August 26, 2026; effective date is Aug 28."
  },
  {
   "id": "R2-21",
   "ticker": "SER",
   "category": "cash",
   "answer": "$23,024 thousand (about $23.0 million).",
   "accepted_variants": [
    "$23.0 million",
    "$23,024,000",
    "23,024"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001708599-26-000047",
     "form": "10-Q",
     "filing_date": "2026-08-13",
     "url": "https://www.sec.gov/Archives/edgar/data/1708599/000170859926000047/ser-20260630.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1708599/000170859926000047/"
    }
   ],
   "supporting_passage": "NC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par value amounts) June 30, 2026 December 31, 2025 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 23,024 $ 3,056 Prepaid expenses and other current assets 2,006 3,024 Total current assets 25,030 6,080 Property and equipment, net 482 465 Right of use assets - operating leases 277 377 Other long-term prep ... ely $21.2 million, and we have also raised capital under our at-the-market offering program. As of June 30, 2026, we had cash and cash equivalents of approximately $23.0 million, total stockholders’ equity of approximately $18.7 million and an accumulated deficit of approximately $76.8 million. Management has concluded that our existing cash and cash equivalents are not expe",
   "xbrl_facts": [
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 23024000,
     "period_end": "2026-06-30"
    },
    {
     "tag": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "value": 23024000,
     "period_end": "2026-06-30"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Up from $3,056 thousand at December 31, 2025 (March/April 2026 PIPE)."
  },
  {
   "id": "R2-22",
   "ticker": "JSPR",
   "category": "cash",
   "answer": "$7,314 thousand (about $7.3 million) cash and cash equivalents at June 30, 2026.",
   "accepted_variants": [
    "$7.3 million",
    "$7,314,000",
    "7,314"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-089592",
     "form": "10-Q",
     "filing_date": "2026-08-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1788028/000121390026089592/ea0300872-10q_jasper.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1788028/000121390026089592/"
    }
   ],
   "supporting_passage": "DENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) (unaudited) June 30, December 31, 2026 2025 Assets Current assets: Cash and cash equivalents $ 7,314 $ 28,692 Restricted cash, current 417 — Prepaid expenses and other current assets 3,840 5,953 Total current assets 11,571 34,645 Property and equipment, net 60 102 Operating lease right-of-use assets ... 3 million. In July 2026, the Company completed a private placement financing through the sale of non-voting convertible preferred stock, resulting in gross proceeds of $ 132.0 million (see Note 15). The Company has agreed to seek a stockholder vote to convert the Non-Voting Convertible Preferred Stock within 120 days from the closing of the merger. In addition, in the event the Co",
   "xbrl_facts": [
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 7314000,
     "period_end": "2026-06-30"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: a July 2026 private placement raised $132.0 million gross AFTER the balance sheet date; restricted cash ($417 thousand) is separate."
  },
  {
   "id": "R2-23",
   "ticker": "MIRA",
   "category": "cash",
   "answer": "Cash of $3,609,442 at June 30, 2026 (about $3.6 million); yes, the filing states substantial doubt about its ability to continue as a going concern.",
   "accepted_variants": [
    "$3.6 million",
    "$3,609,442",
    "going concern: yes"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-037366",
     "form": "10-Q",
     "filing_date": "2026-08-12",
     "url": "https://www.sec.gov/Archives/edgar/data/1904286/000149315226037366/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1904286/000149315226037366/"
    }
   ],
   "supporting_passage": "NCIAL INFORMATION MIRA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2026 2025 (unaudited) ASSETS Current assets: Cash $ 3,609,442 $ 6,346,921 Prepaid expenses 54,286 28,146 Short-term investments – related party 4,503,973 4,683,099 Total current assets 8,167,701 11,058,166 Related party receivable 35,439 35,439 Total assets $ 8 ... o support its operations for at least the 12 months following the date these unaudited condensed financial statements are issued. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Quarterly Report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow p",
   "xbrl_facts": [
    {
     "tag": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "value": 3609442,
     "period_end": "2026-06-30"
    },
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 3609442,
     "period_end": "2026-06-30"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-24",
   "ticker": "CLRO",
   "category": "cash",
   "answer": "$75 thousand ($75,000) of cash and cash equivalents; restricted cash was a separate $447 thousand.",
   "accepted_variants": [
    "$75,000",
    "$75 thousand",
    "75"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001753926-26-001521",
     "form": "10-Q",
     "filing_date": "2026-08-14",
     "url": "https://www.sec.gov/Archives/edgar/data/840715/000175392626001521/clro-20260630.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/840715/000175392626001521/"
    }
   ],
   "supporting_passage": ", INC UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in thousands, except par value) June 30, 2026 December 31, 2025 ASSETS Current assets: Cash and cash equivalents $ 75 $ 220 Restricted cash 447 519 Inventories, net 304 353 Prepaid assets 10 — Current assets related to discontinued operations 140 604 Total current assets 976 1,696 Operating lease - right of use assets, ne ... D BALANCE SHEETS (Dollars in thousands, except par value) June 30, 2026 December 31, 2025 ASSETS Current assets: Cash and cash equivalents $ 75 $ 220 Restricted cash 447 519 Inventories, net 304 353 Prepaid assets 10 — Current assets related to discontinued operations 140 604 Total current assets 976 1,696 Operating lease - right of use assets, net — 494 Long term as",
   "xbrl_facts": [
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 75000,
     "period_end": "2026-06-30"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Statements are in thousands; trap is adding restricted cash ($447K)."
  },
  {
   "id": "R2-25",
   "ticker": "TPST",
   "category": "cash",
   "answer": "$779 thousand of cash and cash equivalents at June 30, 2026 (down from $7,707 thousand at December 31, 2025); yes, substantial doubt exists.",
   "accepted_variants": [
    "$779,000",
    "$0.8 million",
    "779"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001193125-26-349381",
     "form": "10-Q",
     "filing_date": "2026-08-13",
     "url": "https://www.sec.gov/Archives/edgar/data/1544227/000119312526349381/tpst-20260630.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1544227/000119312526349381/"
    }
   ],
   "supporting_passage": "sed Consolidated Balance Sheets (in thousands, except share and per share amounts) June 30, 2026 (Unaudited) December 31, 2025 Assets Current assets: Cash and cash equivalents $ 779 $ 7,707 Prepaid expenses and other current assets 918 562 Total current assets 1,697 8,269 Property and equipment — net 486 605 Operating lease right-of-use assets 6,949 7,540 Other noncurrent assets 501 517 ... rating expense requirements through less than 12 months from the date our consolidated financial statements were available to be issued. Accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern for a period of 12 months from the date of issuance of these consolidated financial statements. The accompanying financial statements were prepared on a going concern basis, which contemplates the re",
   "xbrl_facts": [
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 779000,
     "period_end": "2026-06-30"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-26",
   "ticker": "HLYK",
   "category": "cash",
   "answer": "$12,844 (down from $37,136 at December 31, 2025).",
   "accepted_variants": [
    "$12,844",
    "12,844"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-090221",
     "form": "10-Q",
     "filing_date": "2026-08-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1680139/000121390026090221/ea0301072-10q_health.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1680139/000121390026090221/"
    }
   ],
   "supporting_passage": "em 1. Financial Statements HEALTHLYNKED CORP. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2026 2025 (Unaudited) ASSETS Current Assets Cash $ 12,844 $ 37,136 Inventory, net 18,300 17,962 Prepaid expenses and other current assets 50,176 32,935 Contingent sale consideration receivable 1,463,518 1,463,518 Total Current Assets 1,544,838 1,551,551 Property and",
   "xbrl_facts": [
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 12844,
     "period_end": "2026-06-30"
    },
    {
     "tag": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "value": 12844,
     "period_end": "2026-06-30"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-27",
   "ticker": "SDST",
   "category": "cash",
   "answer": "$540,264 (down from $3,480,151 at December 31, 2025).",
   "accepted_variants": [
    "$540,264",
    "540,264"
   ],
   "as_of": "June 30, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-037856",
     "form": "10-Q",
     "filing_date": "2026-08-13",
     "url": "https://www.sec.gov/Archives/edgar/data/1831979/000149315226037856/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1831979/000149315226037856/"
    }
   ],
   "supporting_passage": " BALANCE SHEETS (all amounts in USD, except number of shares) As of June 30, 2026 As of December 31, 2025 (unaudited) (audited) ASSETS Current assets Cash $ 540,264 $ 3,480,151 Prepaid expenses and other current assets 264,269 573,834 Deferred transaction costs 104,291 25,000 Total current assets $ 908,824 $ 4,078,985 Property and equipment, net 1,782,505 1,757,271 Capital ",
   "xbrl_facts": [
    {
     "tag": "CashAndCashEquivalentsAtCarryingValue",
     "value": 540264,
     "period_end": "2026-06-30"
    },
    {
     "tag": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "value": 540264,
     "period_end": "2026-06-30"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-28",
   "ticker": "ISPC",
   "category": "cash",
   "answer": "$4,051,471 of net cash used in operating activities (six months ended June 30, 2026; prior-year period $1,288,079).",
   "accepted_variants": [
    "$4,051,471",
    "4,051,471",
    "$4.05 million"
   ],
   "as_of": "Six months ended June 30, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-090226",
     "form": "10-Q",
     "filing_date": "2026-08-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1558569/000121390026090226/ea0301425-10q_ispecimen.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1558569/000121390026090226/"
    }
   ],
   "supporting_passage": "s payable ( 429,127 ) 117,449 Accrued expenses 28 ( 523,219 ) Operating lease liability ( 27,895 ) ( 24,282 ) Deferred revenue ( 67,839 ) ( 196,642 ) Net cash used in operating activities ( 4,051,471 ) ( 1,288,079 ) CASH FLOWS FROM INVESTING ACTIVITIES: Capitalization of internally developed software ( 700,000 ) — Purchase of property and equipment — ( 454 ) Net cash used in investing activities ( 700,000 ) ( 45",
   "xbrl_facts": [
    {
     "tag": "NetCashProvidedByUsedInOperatingActivities",
     "value": -4051471,
     "period_end": "2026-06-30"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-29",
   "ticker": "GTBP",
   "category": "shares_float",
   "answer": "45,109,497 shares as of August 10, 2026 (as filed; not adjusted for any later reverse split).",
   "accepted_variants": [
    "45,109,497"
   ],
   "as_of": "August 10, 2026",
   "primary_source": [
    {
     "accession": "0001493152-26-037988",
     "form": "10-Q",
     "filing_date": "2026-08-14",
     "url": "https://www.sec.gov/Archives/edgar/data/109657/000149315226037988/form10-q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/109657/000149315226037988/"
    }
   ],
   "supporting_passage": "a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ As of August 10, 2026, the registrant had 45,109,497 shares of common stock outstanding. 1 Effective as of July 1, 2024, the Company became a fully remote company. We do not maintain a principal executive office. For purposes of compliance with applicable requirements of the Securities ",
   "xbrl_facts": [
    {
     "tag": "EntityCommonStockSharesOutstanding",
     "value": 45109497,
     "period_end": "2026-08-10"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: the company filed a separate 8-K (0001493152-26-041333, 2026-09-03) reporting a 1-for-25 reverse split after this 10-Q; a split-adjusted count is not what the 10-Q reports."
  },
  {
   "id": "R2-30",
   "ticker": "ADGM",
   "category": "shares_float",
   "answer": "22,210,459 shares as of August 10, 2026 (as filed; not adjusted for any later reverse split).",
   "accepted_variants": [
    "22,210,459"
   ],
   "as_of": "August 10, 2026",
   "primary_source": [
    {
     "accession": "0001104659-26-093790",
     "form": "10-Q",
     "filing_date": "2026-08-11",
     "url": "https://www.sec.gov/Archives/edgar/data/2006986/000110465926093790/adgm-20260630x10q.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/2006986/000110465926093790/"
    }
   ],
   "supporting_passage": "a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ As of August 10, 2026, there were 22,210,459 shares of common stock, $0.0001 par value, issued and outstanding. Table of Contents Table of Contents ADAGIO MEDICAL HOLDINGS, INC. FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2026 TABLE OF CONTENTS Page PART I: FINANCIAL IN",
   "xbrl_facts": [
    {
     "tag": "EntityCommonStockSharesOutstanding",
     "value": 22210459,
     "period_end": "2026-08-10"
    },
    {
     "tag": "CommonStockSharesIssued",
     "value": 22210459,
     "period_end": "2025-12-31"
    },
    {
     "tag": "CommonStockSharesIssued",
     "value": 22210459,
     "period_end": "2026-06-30"
    },
    {
     "tag": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "value": 22210459,
     "period_end": "2026-06-30"
    },
    {
     "tag": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "value": 22210459,
     "period_end": "2026-06-30"
    },
    {
     "tag": "WeightedAverageNumberOfSharesOutstandingBasic",
     "value": 22210459,
     "period_end": "2026-06-30"
    },
    {
     "tag": "WeightedAverageNumberOfSharesOutstandingBasic",
     "value": 22210459,
     "period_end": "2026-06-30"
    },
    {
     "tag": "CommonStockSharesOutstanding",
     "value": 22210459,
     "period_end": "2025-12-31"
    },
    {
     "tag": "CommonStockSharesOutstanding",
     "value": 22210459,
     "period_end": "2026-06-30"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: a later 8-K (0001104659-26-123074, 2026-11-05) reports a 1-for-30 reverse split; post-split share counts differ from the 10-Q figure."
  },
  {
   "id": "R2-31",
   "ticker": "SXTP",
   "category": "shares_float",
   "answer": "3,516,988 shares as of August 14, 2026.",
   "accepted_variants": [
    "3,516,988"
   ],
   "as_of": "August 14, 2026",
   "primary_source": [
    {
     "accession": "0001554855-26-001860",
     "form": "10-Q",
     "filing_date": "2026-08-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1946563/000155485526001860/sxtp-20260630.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1946563/000155485526001860/"
    }
   ],
   "supporting_passage": "(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒ As of August 14, 2026 , the registrant had a total of 3,516,988 shares of its common stock, par value $0.0001 per share, issued and shares outstanding. INDEX Page PART I. FINANCIAL INFORMATION 1 Item 1. Consolidated Conde ... her the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒ As of August 14, 2026 , the registrant had a total of 3,516,988 shares of its common stock, par value $0.0001 per share, issued and shares outstanding. INDEX Page PART I. FINANCIAL INFORMATION 1 Item 1. Consolidated Condensed Financial Statements (unaudited) 1 Consolida",
   "xbrl_facts": [
    {
     "tag": "EntityCommonStockSharesOutstanding",
     "value": 3516988,
     "period_end": "2026-08-14"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-32",
   "ticker": "CVKD",
   "category": "shares_float",
   "answer": "3,567,592 shares as of August 13, 2026.",
   "accepted_variants": [
    "3,567,592"
   ],
   "as_of": "August 13, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-089153",
     "form": "10-Q",
     "filing_date": "2026-08-13",
     "url": "https://www.sec.gov/Archives/edgar/data/1937993/000121390026089153/ea0301223-10q_cadrenal.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1937993/000121390026089153/"
    }
   ],
   "supporting_passage": "a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ As of August 13, 2026, there were 3,567,592 outstanding shares of common stock, par value $0.001 per share, of Cadrenal Therapeutics, Inc. CADRENAL THERAPEUTICS, INC. QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2026 TABLE OF CONTENTS Page PART I. FINAN",
   "xbrl_facts": [
    {
     "tag": "EntityCommonStockSharesOutstanding",
     "value": 3567592,
     "period_end": "2026-08-13"
    }
   ],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-33",
   "ticker": "BTLN",
   "category": "shares_float",
   "answer": "Approximately $16,769,000 as of December 31, 2025 (based on a closing price of $0.926 per share on that date).",
   "accepted_variants": [
    "$16,769,000",
    "$16.8 million"
   ],
   "as_of": "December 31, 2025 (last business day of second fiscal quarter)",
   "primary_source": [
    {
     "accession": "0001493152-26-044574",
     "form": "10-K",
     "filing_date": "2026-09-28",
     "url": "https://www.sec.gov/Archives/edgar/data/1854445/000149315226044574/form10-k.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1854445/000149315226044574/"
    }
   ],
   "supporting_passage": "eriod pursuant to §240.10D-1(b). ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No As of December 31, 2025, the aggregate market value of the registrant’s voting and non-voting common equity held by non-affiliates of the registrant was approximately $ 16,769,000 based on the closing sale price as reported on the Nasdaq Capital Market of $0.926 per share. As of September 28, 2026, 2,712,351 shares of the registrant’s common stock were issued and outstanding.  ... y held by non-affiliates of the registrant was approximately $ 16,769,000 based on the closing sale price as reported on the Nasdaq Capital Market of $0.926 per share. As of September 28, 2026, 2,712,351 shares of the registrant’s common stock were issued and outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement f",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: a separate 8-K (0001493152-26-043847, 2026-09-23) reports a 1-for-8 reverse split, so the $0.926 price is pre-split; 2,712,351 shares outstanding at Sept 28, 2026 is post-split and a different figure."
  },
  {
   "id": "R2-34",
   "ticker": "POCI",
   "category": "shares_float",
   "answer": "6,110,561 shares held by non-affiliates, with an aggregate market value of approximately $25,603,000, based on a $4.19 closing price on December 31, 2025.",
   "accepted_variants": [
    "6,110,561",
    "$25,603,000",
    "$25.6 million"
   ],
   "as_of": "December 31, 2025",
   "primary_source": [
    {
     "accession": "0001683168-26-007462",
     "form": "10-K",
     "filing_date": "2026-09-28",
     "url": "https://www.sec.gov/Archives/edgar/data/867840/000168316826007462/poci_i10k-063026.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/867840/000168316826007462/"
    }
   ],
   "supporting_passage": "t.) ☐ Yes ☒ No The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant on December 31, 2025 was approximately $ 25,603,000 based on a total of 6,110,561 shares of the registrant’s common stock held by non-affiliates on such date, at the closing price of $4.19 per share, as reported on Nasdaq on December 31, 2025. The number of shares of outstanding common s ... ately $ 25,603,000 based on a total of 6,110,561 shares of the registrant’s common stock held by non-affiliates on such date, at the closing price of $4.19 per share, as reported on Nasdaq on December 31, 2025. The number of shares of outstanding common stock of the registrant as of September 20, 2026 was 10,972,792 . Documents incorporated by reference Portions ",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: total shares outstanding at June 30, 2026 was 10,972,792, a different figure."
  },
  {
   "id": "R2-35",
   "ticker": "GTEC",
   "category": "other_8k",
   "answer": "No. In a Form 8-K filed September 23, 2026 (Item 8.01), the company reported Nasdaq notified it on September 22, 2026 that it had regained compliance with the minimum bid price requirement (closing bid at or above $1.00 for 10 consecutive business days, September 8 through September 21, 2026) and the matter is closed. This supersedes the September 11, 2026 8-K (Item 3.01) that gave a Second Compliance Period until March 8, 2027.",
   "accepted_variants": [
    "regained compliance",
    "matter is closed",
    "September 22, 2026"
   ],
   "as_of": "September 22, 2026 (Nasdaq letter); 8-K filed September 23, 2026",
   "primary_source": [
    {
     "accession": "0001213900-26-102404",
     "form": "8-K",
     "filing_date": "2026-09-23",
     "url": "https://www.sec.gov/Archives/edgar/data/1735041/000121390026102404/ea0306386-8k_greenland.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1735041/000121390026102404/"
    }
   ],
   "supporting_passage": ", if necessary. On September 22, 2026, the Company received a letter from Nasdaq notifying the Company that the Staff has determined that the Company has regained compliance with the Minimum Bid Price Requirement as a result of the closing bid price of the Class A Ordinary Shares being at $1.00 per share or greater for 10 consecutive business days from September 8, 2026 through September 21, 2026. Accordingly ... irement as a result of the closing bid price of the Class A Ordinary Shares being at $1.00 per share or greater for 10 consecutive business days from September 8, 2026 through September 21, 2026. Accordingly, the Company is in compliance with the Minimum Bid Price Requirement, and the matter is now closed. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: the earlier Sept 11, 2026 8-K (0001213900-26-099268) shows a compliance deadline of March 8, 2027, which no longer applies."
  },
  {
   "id": "R2-36",
   "ticker": "AUID",
   "category": "other_8k",
   "answer": "Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price); the initial 180-calendar-day compliance period runs until February 23, 2027 (notice received August 27, 2026).",
   "accepted_variants": [
    "5550(a)(2)",
    "bid price",
    "February 23, 2027"
   ],
   "as_of": "Notice dated August 27, 2026; deadline February 23, 2027",
   "primary_source": [
    {
     "accession": "0001213900-26-096295",
     "form": "8-K",
     "filing_date": "2026-09-01",
     "url": "https://www.sec.gov/Archives/edgar/data/1534154/000121390026096295/ea0304306-8k_authid.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1534154/000121390026096295/"
    }
   ],
   "supporting_passage": "the Company’s common stock was below the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The Notice has no immediate effect on the listing or trading of the Company’s common stock, which continues to trade on the Nasdaq Capital Market under the symbol “AUID.” In a ... th Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days from the date of the Notice, or until February 23, 2027, to regain compliance with the Bid Price Rule. If, at any time during this 180-day period, the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of ten consecu",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": null
  },
  {
   "id": "R2-37",
   "ticker": "BURU",
   "category": "other_amended",
   "answer": "Net loss of $5,714,861 as restated (originally reported $6,475,862; adjustment $761,001 for the fair value of the Tekne Convertible Note Receivable).",
   "accepted_variants": [
    "$5,714,861",
    "5,714,861",
    "$5.7 million"
   ],
   "as_of": "Three months ended June 30, 2026",
   "primary_source": [
    {
     "accession": "0001193125-26-396895",
     "form": "10-Q/A",
     "filing_date": "2026-09-22",
     "url": "https://www.sec.gov/Archives/edgar/data/1814215/000119312526396895/buru-20260630.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1814215/000119312526396895/"
    }
   ],
   "supporting_passage": "alue of convertible notes receivable $ 288,535 $ 761,001 $ 1,049,536 Loss before provision for income taxes $ ( 6,475,862 ) $ 761,001 $ ( 5,714,861 ) Net loss $ ( 6,475,862 ) $ 761,001 $ ( 5,714,861 ) Comprehensive loss $ ( 6,441,021 ) $ 761,001 $ ( 5,680,020 ) Net loss available to common shareholders $ ( 8,049,174 ) $ 761,001 $ ( 7,288,173 ) Net loss per common share, basic and diluted (1) $ ( 0",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: the original 10-Q (filed Aug 14, 2026) reported $6,475,862; the amendment supersedes it. Per-share figures are also restated for the 1-for-40 split of September 1, 2026."
  },
  {
   "id": "R2-38",
   "ticker": "PLUR",
   "category": "other_offering",
   "answer": "Combined purchase price $1.50 per Common Share and accompanying warrant ($1.49999 per pre-funded warrant and warrant); warrants (up to 2,228,940 shares) have an exercise price of $1.65 per share.",
   "accepted_variants": [
    "$1.50",
    "$1.65"
   ],
   "as_of": "August 26-28, 2026 (offering priced; supplement filed August 28, 2026)",
   "primary_source": [
    {
     "accession": "0001213900-26-094704",
     "form": "424B5",
     "filing_date": "2026-08-28",
     "url": "https://www.sec.gov/Archives/edgar/data/1158780/000121390026094704/ea0303747-424b5_pluri.htm",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1158780/000121390026094704/"
    }
   ],
   "supporting_passage": "ive and a half years from issuance. Each Common Share or Pre-Funded Warrant is being sold together with one Warrant to purchase one Common Share. The combined purchase price per Common Share and privately placed accompanying Warrant is $1.50. The combined purchase price per Pre-Funded Warrant and privately placed accompanying Warrant is $1.49999, which is equal to the combined purchase price per Common Share and privately placed accompan ... e Concurrent Private Placement, we are issuing unregistered warrants to purchase up to 2,228,940 Common Shares, or the Warrants. The Warrants have an exercise price of $1.65 per share, are exercisable six months following their issuance, and will expire five and a half years from issuance. Each Common Share or Pre-Funded Warrant is being sold together with one Warrant to purchase ",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Trap: last reported sale price was $1.48; the non-affiliate market value paragraph uses $2.18."
  },
  {
   "id": "R2-39",
   "ticker": "LTRN",
   "category": "other_insider",
   "answer": "Yes. Directors Lee Troy Schalop and D. Jeffrey Keyser each reported purchasing 48,544 shares of common stock at $2.06 on May 12, 2026 (97,088 shares combined, transaction code P), each alongside a warrant for 48,544 shares at $2.27.",
   "accepted_variants": [
    "97,088",
    "48,544 each"
   ],
   "as_of": "May 12, 2026 (Forms 4 filed May 14, 2026)",
   "primary_source": [
    {
     "accession": "0001493152-26-023083",
     "form": "4",
     "filing_date": "2026-05-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226023083/ownership.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226023083/"
    },
    {
     "accession": "0001493152-26-023082",
     "form": "4",
     "filing_date": "2026-05-14",
     "url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226023082/ownership.xml"
    }
   ],
   "supporting_passage": "Form 4 0001493152-26-023083 (Schalop Lee Troy, director): nonDerivative transaction 2026-05-12 code P, 48544 shares @ 2.06; Form 4 0001493152-26-023082 (KEYSER D JEFFREY, director): 2026-05-12 code P, 48544 shares @ 2.06; each also lists a derivative warrant (right to buy) 48544 @ 2.27",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": "Warrant acquisitions on the same Form 4s (48,544 each at $2.27 exercise price) are derivative lines, not additional common shares."
  },
  {
   "id": "R2-40",
   "ticker": "NSPR",
   "category": "other_insider",
   "answer": "Yes. CEO and President Marvin Slosman reported a code P purchase of 21,000 shares of common stock at $1.20 per share on May 12, 2026 (Form 4 filed May 13, 2026).",
   "accepted_variants": [
    "21,000 shares",
    "$1.20"
   ],
   "as_of": "May 12, 2026 (Form 4 filed May 13, 2026)",
   "primary_source": [
    {
     "accession": "0001493152-26-022775",
     "form": "4",
     "filing_date": "2026-05-13",
     "url": "https://www.sec.gov/Archives/edgar/data/1433607/000149315226022775/ownership.xml",
     "index_url": "https://www.sec.gov/Archives/edgar/data/1433607/000149315226022775/"
    }
   ],
   "supporting_passage": "Form 4 0001493152-26-022775 (Slosman Marvin, director and officer 'CEO and President'): nonDerivative transaction 2026-05-12, code P, 21000 shares @ 1.20",
   "xbrl_facts": [],
   "verified_against_primary_filing": true,
   "trap_note": null
  }
 ]
}